Jamie Coborn1,2, Anouk de Wit1,3, Sybil Crawford4, Margo Nathan1,2, Shadab Rahman2,5,6, Lauren Finkelstein1, Aleta Wiley1,2, Hadine Joffe1,2. 1. Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, United States. 2. Connors Center for Women's Health and Gender Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, United States. 3. Department of Psychiatry, University of Groningen/ University Medical Center Groningen, Groningen, Netherlands. 4. Tan Chingfen Graduate School of Nursing at UMass Chan Medical School, Worcester, MA, 01605, United States. 5. Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, 02115, United States. 6. Division of Sleep Medicine, Harvard Medical School, Boston, MA, 02115, United States.
Abstract
CONTEXT: Nocturnal vasomotor symptoms (nVMS), depressive symptoms (DepSx), and female reproductive hormone changes contribute to perimenopause-associated disruption in sleep continuity. Hormonal changes underlie both nVMS and DepSx. However, their association with sleep continuity parameters resulting in perimenopause-associated sleep disruption remains unclear. OBJECTIVE: We aimed to determine the association between female reproductive hormones and perimenopausal sleep discontinuity independent of nVMS and DepSx. METHODS: Daily sleep and VMS diaries, and weekly serum assays of female reproductive hormones were obtained for 8 consecutive weeks in 45 perimenopausal women with mild DepSx but no primary sleep disorder. Generalized estimating equations were used to examine associations of estradiol, progesterone, and follicle stimulating hormone (FSH) with mean number of nightly awakenings, wakefulness after sleep onset (WASO) and sleep-onset latency (SOL) adjusting for nVMS and DepSx. RESULTS: Sleep disruption was common (median 1.5 awakenings/night, WASO 24.3 and SOL 20.0 minutes). More awakenings were associated with estradiol levels in the postmenopausal range (β = 0.14; 95% CI, 0.04 to 0.24; P = 0.007), and higher FSH levels (β [1-unit increase] = 0.12; 95% CI, 0.02 to 0.22; P = 0.02), but not with progesterone (β [1-unit increase] = -0.02; 95% CI, -0.06 to 0.01; P = 0.20) in adjusted models. Female reproductive hormones were not associated with WASO or SOL. CONCLUSION: Associations of more awakenings with lower estradiol and higher FSH levels provide support for a perimenopause-associated sleep discontinuity condition that is linked with female reproductive hormone changes, independent of nVMS and DepSx.
CONTEXT: Nocturnal vasomotor symptoms (nVMS), depressive symptoms (DepSx), and female reproductive hormone changes contribute to perimenopause-associated disruption in sleep continuity. Hormonal changes underlie both nVMS and DepSx. However, their association with sleep continuity parameters resulting in perimenopause-associated sleep disruption remains unclear. OBJECTIVE: We aimed to determine the association between female reproductive hormones and perimenopausal sleep discontinuity independent of nVMS and DepSx. METHODS: Daily sleep and VMS diaries, and weekly serum assays of female reproductive hormones were obtained for 8 consecutive weeks in 45 perimenopausal women with mild DepSx but no primary sleep disorder. Generalized estimating equations were used to examine associations of estradiol, progesterone, and follicle stimulating hormone (FSH) with mean number of nightly awakenings, wakefulness after sleep onset (WASO) and sleep-onset latency (SOL) adjusting for nVMS and DepSx. RESULTS: Sleep disruption was common (median 1.5 awakenings/night, WASO 24.3 and SOL 20.0 minutes). More awakenings were associated with estradiol levels in the postmenopausal range (β = 0.14; 95% CI, 0.04 to 0.24; P = 0.007), and higher FSH levels (β [1-unit increase] = 0.12; 95% CI, 0.02 to 0.22; P = 0.02), but not with progesterone (β [1-unit increase] = -0.02; 95% CI, -0.06 to 0.01; P = 0.20) in adjusted models. Female reproductive hormones were not associated with WASO or SOL. CONCLUSION: Associations of more awakenings with lower estradiol and higher FSH levels provide support for a perimenopause-associated sleep discontinuity condition that is linked with female reproductive hormone changes, independent of nVMS and DepSx.
Authors: M W L Morssinkhof; D W van Wylick; S Priester-Vink; Y D van der Werf; M den Heijer; O A van den Heuvel; B F P Broekman Journal: Neurosci Biobehav Rev Date: 2020-08-31 Impact factor: 8.989
Authors: Karen A Matthews; Martica H Hall; Laisze Lee; Howard M Kravitz; Yuefang Chang; Bradley M Appelhans; Leslie M Swanson; Genevieve S Neal-Perry; Hadine Joffe Journal: Sleep Date: 2019-05-01 Impact factor: 5.849
Authors: Howard M Kravitz; Imke Janssen; Nanette Santoro; Joyce T Bromberger; Miriam Schocken; Susan A Everson-Rose; Kelly Karavolos; Lynda H Powell Journal: Arch Intern Med Date: 2005-11-14
Authors: Marissa A Bowman; Christopher E Kline; Daniel J Buysse; Howard M Kravitz; Hadine Joffe; Karen A Matthews; Joyce T Bromberger; Kathryn A Roecklein; Robert T Krafty; Martica H Hall Journal: Ann Behav Med Date: 2021-06-28